HSP90B2P and AL amyloidosis: The disruption of both HSP synthesis and general protein degradation, will likely have an additive effect on eliminating cancer cells, and might even aid in the prevention of drug resistance, which commonly develops in multiple myeloma patients treated with Bortezomib [145].